Pfizer has completed the acquisition of Baxter International’s vaccines portfolio. The portfolio includes NeisVac-C and FSME-IMMUN/TicoVac. Pfizer also acquired a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured.   NeisVac-C helps protect against meningitis caused by group C meningococci(MenC), and FSME-IMMUN/TicoVac helps protect against tick-borne encephalitis (TBE), an infection of the brain transmitted by the bite of ticks infected with the TBE-virus.   “N...